Evidence for or against efficacy of beta-blockers and aspirin for management of feline cardiomyopathies.
Feline myocardial diseases today are largely represented by disorders involving LV hypertrophy. They may be attended by arrhythmias, congestive heart failure, systemic hypertension, thromboembolic complications, and sudden death. These structural myocardial disorders and their hemodynamic and electrocardiographic derangements may cause or result in variable degrees of diastolic dysfunction. Propranolol and aspirin represent two agents commonly employed to treat feline cardiomyopathies for more than 15 years. Nevertheless, clinical data describing their effect on morbidity and mortality are lacking. It is likely that propranolol administered at moderate to high doses effects favorable responses in some cats with clinical signs attributable to severe hypertrophy, outflow obstruction, or tachyarrhythmias. It is unknown whether clinical improvements are due to direct myocardial effects or (more likely) secondary responses to a beta-adrenergic blockade reduction in heart rate or contractility. Personal experience also indicates that high numbers of cats have received the drug for many years in combination with other therapies (especially furosemide) and remain in a compensated state of heart failure without untoward drug effects. On the other hand, many cardiomyopathic cats experience heart failure, arrhythmias, and death despite treatment with beta-blocking agents. Feline thromboembolism is a devastating complication of cardiomyopathic disorders. Until or unless the primary cause(s) of current diseases is elucidated to promote disease reversal, factors responsible for thrombus formation will accompany the heart diseases, protected from effective management. It appears unlikely that aspirin as currently recommended produces any obvious benefit in treating or preventing thromboembolism. Modifications of therapeutic protocols prescribing these frequently used drugs await well-constructed clinical trials evaluating their efficacy with respect to cardiovascular morbidity and mortality.
Department of Clinic Services, New York Hospital, Cornell Medical Center, New York.
P R
PR
Fox
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use*; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D011433:Propranolol / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*
D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D001241:Aspirin